Drug Trial Radar · NCT07197606
Clinical Trial of Umbilical Cord Mesenchymal Stem Cells in Subacute Ischemic Stroke
Last checked: Nov 19, 2026Latest source record: Sep 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
86
Planned (sponsor's estimate)
Start
Oct 1, 2025
Primary completion
Jun 30, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Shanghai IxCell Biotechnology Co., LTDAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 29, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate the efficacy, safety, and pharmacodynamic characteristics of Human Umbilical Cord Mesenchymal Stem Cells (hUC-MSCs) in adults with ischemic stroke in the anterior circulation during the recovery phase. Researchers will compare hUC-MSCs to a placebo to determine whether hUC-MSCs treatment is effective in treating recovery-phase anterior circulation ischemic stroke.
Conditions
- Ischemic Stroke
Interventions
PlaceboDrug
Intravenous injection of placebo
IxCell hUC-MSC-S (Human Umbilical Cord Mesenchymal Stem Cells)Drug
Intravenous injection of IxCell hUC-MSC-S
Primary outcomes
What the sponsor says the trial is designed to measure.
- Fugl-Meyer Assessment motor scoreTime frame: 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Xuanwu Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.